Metabolism - Clinical and Experimental This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation?
Non-Alcoholic Fatty Liver Disease (NAFLD) is a highly prevalent disease and unmet clinical need that we have recently proposed to be renamed for simplicity and accuracy as Fatty Liver Disease (FLD), with specific subclassifications. It has been commonly associated with metabolic comorbidities, including obesity, type 2 diabetes (T2D), hypertension, and hyperlipidemia. Since no Federal and Drug Administration (FDA) approved treatments exist to date, recent guidelines recommend lifestyle interventions, bariatric surgery, and pharmacotherapy, i.e. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - July 4, 2022 Category: Biomedical Science Authors: Laura Valenzuela-Vallejo, Valentina Guatibonza-Garc ía, Christos S. Mantzoros Source Type: research

Recent guidelines for non-alcoholic fatty liver disease (NAFLD): Are they already outdated and in need of supplementation?
Non-alcoholic fatty liver disease (NAFLD), a highly prevalent disease and unmet clinical need, has been commonly associated with metabolic comorbidities, including obesity, type 2 diabetes (T2D), hypertension, and hyperlipidemia. Since no FDA approved treatments exist to date, recent guidelines recommend lifestyle interventions, bariatric surgery, and pharmacotherapy, i.e., glucagon-like peptide-1 receptor agonists (GLP-1RA), peroxisome proliferator-activated receptor- γ (PPAR-γ) agonists, and SGLT-2 inhibitors for its treatment. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - July 4, 2022 Category: Biomedical Science Authors: Laura Valenzuela-Vallejo, Valentina Guatibonza-Garc ía, Christos S. Mantzoros Source Type: research

Editorial Board
(Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - July 2, 2022 Category: Biomedical Science Source Type: research

Transplantation of bone marrow cells from miR150 knockout mice improves senescence-associated humoral immune dysfunction and arterial stiffness
The senescence-accelerated mouse P1 (SAMP1) suffers from humoral immune deficiency, arterial stiffness and accelerated aging. In contrast, the microRNA-150 knockout (miR-150-KO) mice show enhanced humoral immune function including increased B cell population and elevated serum immunoglobulin levels and enjoy extended lifespan. The purpose of this study was to investigate whether transplantation of bone marrow cells (BMCs) from miR-150-KO mice affects immune deficiency and arterial stiffening in SAMP1 mice. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - July 2, 2022 Category: Biomedical Science Authors: Jun Fan, Shirley Wang, Xianglan Lu, Zhongjie Sun Source Type: research

The continuum of insulin development viewed in the context of a collaborative process toward leveraging science to save lives
Nearly 100 years ago, diabetes, a disease expected to reach global prevalence of at least 10% within the decade, was a fatal diagnosis. This year of 2022 marks a century since insulin, a lifesaving treatment for those living with diabetes, was purified, tested in humans, and brought to the bedside through widespread commercial production, thus saving countless lives. Insulin ’s arrival to the world stage was acknowledged with the 1923 Nobel Prize in Physiology or Medicine for “the discovery of insulin”, the first among several Prizes awarded to honor scientific work on insulin. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - June 30, 2022 Category: Biomedical Science Authors: Antea DeMarsilis, Christos S. Mantzoros Tags: Editorial Source Type: research